Dmitry Genkin

Zurich, Switzerland – December 11, 2025 – Santersus AG today announced two senior leadership appointments that strengthen the company’s executive and governance capabilities as it advances its NucleoCapture™ toward pivotal clinical development. James Ladtkow Appointed as Chief Executive Officer Santersus has appointed James Ladtkow as Chief Executive Officer, effective immediately. Mr. Ladtkow (BSME, MBA) brings …

Santersus AG Appoints New Chief Executive Officer and Expands Board of Directors Read More »

Zurich, Switzerland – December 1, 2025 – Santersus AG today announced the successful completion of its Series A financing, led by Norcliffe, a UK life sciences fund with participation from Terumo Ventures. The financing will support the advancement of Santersus’ NucleoCapture™ into pivotal clinical development while accelerating progress across Santersus’ broader pipeline. Santersus has entered …

Santersus AG Completes Series A Financing led by Norcliffe Capital, joined by Terumo Ventures, and Announces Strategic Collaboration with Terumo Corporation and Advancement of NucleoCapture into Pivotal Clinical Development Read More »

Zurich, Switzerland — September 13, 2025 — Santersus AG congratulates its alliance partner OrganOx Ltd on the company’s acquisition by Terumo Corporation in a transaction valued at up to $1.5 billion — a major milestone in the evolution of global transplant technologies. OrganOx is a leader in normothermic machine perfusion (NMP) for liver transplantation, with …

Santersus AG Congratulates OrganOx on Strategic Acquisition by Terumo Corporation — Underscores Ongoing Collaboration in Donor Liver Perfusion Read More »

Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NucleoCapture™ blood purification technology for the treatment of severe, treatment-refractory systemic lupus erythematosus (SLE). This marks the second Breakthrough Device Designation awarded to NucleoCapture™, following earlier recognition for the treatment of sepsis. NucleoCapture™ is an extracorporeal …

Santersus AG Receives Second U.S. FDA Breakthrough Device Designation for NucleoCapture™ in Systemic Lupus Erythematosus Read More »

December 3, 2024 – Santersus AG presented its groundbreaking NucleoCapture technology at the prestigious BRAIN Conference 2024 in London. The event brought together global experts to advance neurovascular research and discuss cutting-edge developments in brain health. Elevated cfDNA levels are associated with brain injuries and disorders, making it a potential biomarker for diagnosing and monitoring …

Santersus AG Showcases Innovation in Brain Health at BRAIN Conference 2024 Read More »

Santersus AG is proud to announce the successful publication of its latest research, “Restoring discarded porcine lungs by ex vivo removal of neutrophil extracellular traps”, in the prestigious Journal of Heart and Lung Transplantation. This innovative work offers a transformative solution to address the global shortage of viable lungs for transplantation, utilizing advanced ex vivo …

Santersus AG Achieves Breakthrough in Lung Transplantation Research Read More »

Santersus AG has been recognized as a National Abstract Winner at the prestigious UK ECPR Summit, held at the Royal Society of Medicine on Monday, September 23rd 2024. The award highlights the company’s pioneering research on selective cell-free DNA/NETs apheresis with NucleoCapture, presented in a highly acclaimed poster at the critical care section of the event. This innovative …

Santersus AG Wins National Abstract Award at UK ECPR Summit for Groundbreaking Research in Critical Care Read More »

In May, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) and Dr. Hussain Abbas (DPhil, Transplant Surgery, University of Oxford) represented Santersus AG in the 2024 International Congress of ILTS, held in Houston (Texas, USA). The main presentation, which got featured in the best of basic science session, investigated the ability of …

Santersus AG Presented at the 2024 International Congress of ILTS in Houston, Texas Read More »

In May, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG in ILTS 2023 Congress on Liver Transplantation, held in Rotterdam where he presented a Santersus study, aimed to investigate the effect of removal of NETs on reduction of ex-situ reperfusion injury in porcine DCD livers preserved with normothermic machine …

Santersus AG continues to present the latest work across the globe, presenting at conferences in Berlin, Rotterdam, Athens, and Milan Read More »

In the beginning of March, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG at BTS conference, held in Edinburgh where he presented a recent Santersus study, aimed to investigate the effect of removal of NETs on reduction of ex-situ reperfusion injury in porcine DCD livers preserved with normothermic machine …

Santersus AG presented at NHSBT Joint Congress, held by British Transplantation Society Read More »